Table 3 Description of patients from C3 and C4 cohorts at the 6-month visit after applying propensity score matching
C3 (n = 75) | C4 (n = 75) | p value | |
|---|---|---|---|
Female, n (%)* | 60 (80.0%) | 61 (81.3%) | 0.836 |
Age at diagnosis, years, median (IQR) | 45.0 (36.0–53.0) | 45.0 (37.0–53.0) | 0.678 |
Age at start of 1st line, years, median (IQR)* | 52.0 (45.0–61.0) | 55.0 (44.0–61.0) | 0.811 |
Disease duration, years, median (IQR)* | 5.0 (2.4–12.7) | 5.8 (3.0–13.1) | 0.937 |
RF positive, n (%)* | 60 (80.0%) | 54 (72.0%) | 0.251 |
Presence of comorbidities, n (%)* | 54 (72.0%) | 55 (73.3%) | 0.855 |
Currently smoking, n (%)* | 21 (28.0%) | 21 (28.0%) | 1.000 |
Number of previous csDMARDs, n (%)* | |||
0 | 2 (2.7%) | 0 (0.0%) | 0.230 |
1 | 16 (21.3%) | 15 (20.0%) | |
2 | 20 (26.7%) | 28 (37.3%) | |
3 | 17 (22.7%) | 20 (26.7%) | |
4+ | 20 (26.7%) | 12 (16.0%) | |
Glucocorticoids in previous history, n (%)* | 67 (89.3%) | 66 (88.0%) | 0.797 |
Concomitant csDMARDs, n (%)* | 61 (81.3%) | 63 (84.0%) | 0.666 |
Concomitant GCs, n (%)* | 56 (74.7%) | 55 (73.3%) | 0.852 |
DAS28-ESR (0–10), median (IQR) | 5.0 (4.2–5.9) | 5.0 (4.1–5.7) | 0.717 |
TJC (28 joints), median (IQR)* | 8.0 (4.0–12.0) | 6.0 (3.0–11.0) | 0.677 |
SJC (28 joints), median (IQR)* | 4.0 (2.0–8.0) | 4.0 (2.0–7.0) | 0.973 |
ESR (mm/h), median (IQR)* | 27.0 (15.0–37.0) | 25.0 (12.0–41.0) | 0.844 |
CRP (mg/l), median (IQR)* | 15.0 (8.0–22.2) | 8.4 (3.5–25.7) | 0.090 |
SDAI (0–86), median (IQR) | 25.5 (15.6–34.9) | 22.7 (16.1–30.9) | 0.531 |
PTGA (0–100), median (IQR)* | 60.0 (40.0–71.0) | 50.0 (40.0–71.0) | 0.519 |
MDGA (0–100), median (IQR) | 55.0 (35.0–70.0) | 45.0 (30.0–60.0) | 0.059 |
HAQ-DI (0–3), median (IQR)* | 1.5 (1.1–1.9) | 1.5 (1.1–1.9) | 0.877 |
EQ-5D (− 0.59–1), median (IQR)a | 0.2 (0.1–0.7) | 0.6 (0.1–0.7) | 0.290 |